You are in the accessibility menu

Please use this identifier to cite or link to this item: http://acervodigital.unesp.br/handle/11449/67806
Full metadata record
DC FieldValueLanguage
dc.contributor.authorScarparo, Ana Cristina-
dc.contributor.authorSumida, Doris Hissako-
dc.contributor.authorPatrão, Marília T. C. C.-
dc.contributor.authorAvellar, Maria Christina W.-
dc.contributor.authorVisconti, Maria Aparecida-
dc.contributor.authorCastrucci, Ana Maria de Lauro-
dc.date.accessioned2014-05-27T11:21:07Z-
dc.date.accessioned2016-10-25T18:19:45Z-
dc.date.available2014-05-27T11:21:07Z-
dc.date.available2016-10-25T18:19:45Z-
dc.date.issued2004-08-01-
dc.identifierhttp://dx.doi.org/10.1007/s00403-004-0488-x-
dc.identifier.citationArchives of Dermatological Research, v. 296, n. 3, p. 112-119, 2004.-
dc.identifier.issn0340-3696-
dc.identifier.urihttp://hdl.handle.net/11449/67806-
dc.identifier.urihttp://acervodigital.unesp.br/handle/11449/67806-
dc.description.abstractThe biological effects of catecholamines in mammalian pigment cells are poorly understood. Our previous results showed the presence of α1-adrenoceptors in SK-Mel 23 human melanoma cells. The aims of this work were to (1) characterize catecholamine effects on proliferation, tyrosinase activity and expression, (2) identify the α1- adrenoceptor subtypes, and (3) verify whether chronic norepinephrine (NE) treatment modified the types and/or pharmacological characteristics of adrenoceptors present in SK-Mel 23 human melanoma cells. Cells treated with the aradrenergic agonist, phenylephrine (PHE, 10-5 or 10-4 M), for 24-72 h, exhibited decreased cell proliferation and enhanced tyrosinase activity, but unaltered tyrosinase expression as compared with the control. The proliferation and tyrosinase activity responses were inhibited by the α1-adrenergic antagonist prazosin, suggesting they were evoked by α1-adrenoceptors. The presence of actinomycin D, a transcription inhibitor, did not diminish PHE-induced effects. RT-PCR assays, followed by cloning and sequencing, demonstrated the presence of α1A- and α1B-adrenoceptor subtypes. NE-treated cells (24 or 72 h) were used in competition assays, and showed no significant change in the competition curves of α1-adrenoceptors as compared with control curves. Other adrenoceptor subtypes were not identified in these cells, and NE pretreatment did not induce their expression. In conclusion, the activation of SK-Mel 23 human melanoma α1- radrenoceptors elicit biological effects, such as proliferation decrease and tyrosinase activity increase. Desensitization or expression of other adrenoceptor subtypes after chronic NE treatment were not observed.en
dc.format.extent112-119-
dc.language.isoeng-
dc.sourceScopus-
dc.subjectα1-Adrenoceptors-
dc.subjectCatecholamines-
dc.subjectCell proliferation-
dc.subjectSK-Mel 23 melanoma cells-
dc.subjectTyrosinase activity-
dc.subjectalpha 1 adrenergic receptor-
dc.subjectalpha 1 adrenergic receptor blocking agent-
dc.subjectalpha 1 adrenergic receptor stimulating agent-
dc.subjectascorbic acid-
dc.subjectbenoxathian-
dc.subjectcatecholamine-
dc.subjectdactinomycin-
dc.subjectmonophenol monooxygenase-
dc.subjectnoradrenalin-
dc.subjectphenylephrine-
dc.subjectprazosin-
dc.subjectadrenergic system-
dc.subjectcatecholamine metabolism-
dc.subjectcell proliferation-
dc.subjectcell strain SK Mel 23-
dc.subjectcontrolled study-
dc.subjectenzyme activity-
dc.subjecthuman-
dc.subjecthuman cell-
dc.subjectmelanoma cell-
dc.subjectpigment cell-
dc.subjectpriority journal-
dc.subjectreverse transcription polymerase chain reaction-
dc.subjectWestern blotting-
dc.subjectAdrenergic alpha-Agonists-
dc.subjectBinding, Competitive-
dc.subjectCell Division-
dc.subjectCell Line, Tumor-
dc.subjectGene Expression-
dc.subjectHumans-
dc.subjectMelanoma-
dc.subjectMonophenol Monooxygenase-
dc.subjectNorepinephrine-
dc.subjectPhenylephrine-
dc.subjectReceptors, Adrenergic, alpha-1-
dc.subjectSkin Neoplasms-
dc.titleCatecholamine effects on human melanoma cells evoked by α1-adrenoceptorsen
dc.typeoutro-
dc.contributor.institutionUniversidade de São Paulo (USP)-
dc.contributor.institutionUniversidade Estadual Paulista (UNESP)-
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)-
dc.description.affiliationDepartamento de Fisiologia Institute de Biociências Universidade de São Paulo, R. do Matão, trav. 14, 321, CEP 05508-900 São Paulo-
dc.description.affiliationDepartamento de Ciencias Basicas Faculdade de Odontologia Universidade Estadual de Sao Paulo, Araçatuba, São Paulo-
dc.description.affiliationSect. of Experimental Endocrinology Department of Pharmacology Univ. Fed. S. P.-Esc. Paulista Med., São Paulo-
dc.description.affiliationUnespDepartamento de Ciencias Basicas Faculdade de Odontologia Universidade Estadual de Sao Paulo, Araçatuba, São Paulo-
dc.identifier.doi10.1007/s00403-004-0488-x-
dc.rights.accessRightsAcesso restrito-
dc.relation.ispartofArchives of Dermatological Research-
dc.identifier.scopus2-s2.0-4344634280-
Appears in Collections:Artigos, TCCs, Teses e Dissertações da Unesp

There are no files associated with this item.
 

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.